Focusing on the renal outcomes in the CV outcome trials revealed that the treatment with SGLT2 inhibitors provided benefits on the renal function, with a significant impact on acute kidney injury (empagliflozin) or death from renal causes (canagliflozin) (10–14). The gene discussed is SLC5A2; the disease is acute kidney injury.